【摘要】：目的:系統(tǒng)評價(jià)氨磷汀預(yù)防化療致周圍神經(jīng)毒性(CIPN)的療效和安全性,為臨床提供循證參考。方法:計(jì)算機(jī)檢索PubMed、EMBase、Cochrane圖書館、相關(guān)期刊論文、萬方數(shù)據(jù)庫和中文科技期刊數(shù)據(jù)庫,收集氨磷汀聯(lián)合化療(試驗(yàn)組)對比單純化療(對照組)用于腫瘤患者的隨機(jī)對照試驗(yàn)(RCT),資料提取并采用改良的Jadad評分量表評價(jià)質(zhì)量后,采用RevMan 5.3統(tǒng)計(jì)軟件進(jìn)行Meta分析。結(jié)果:共納入20項(xiàng)RCT,合計(jì)1 552例患者。Meta分析結(jié)果顯示,試驗(yàn)組患者CIPN總發(fā)生率[RR=0.57,95%CI(0.45,0.72),P0.001]、嚴(yán)重CIPN發(fā)生率[RR=0.47,95%CI(0.32,0.69),P0.001]顯著低于對照組,惡心發(fā)生率[RR=1.31,95%CI(1.03,1.67),P=0.03]、嘔吐發(fā)生率[RR=2.28,95%CI(1.14,4.54),P=0.02]及低血壓發(fā)生率[RR=28.29,95%CI(10.53,76.04),P0.001]顯著高于對照組,差異均有統(tǒng)計(jì)學(xué)意義;兩組患者客觀緩解率比較,差異無統(tǒng)計(jì)學(xué)意義[RR=1.08,95%CI(0.98,1.19),P=0.14]。結(jié)論:氨磷汀能有效預(yù)防腫瘤患者化療致CIPN的發(fā)生,且不影響化療療效,但會(huì)加重患者化療后惡心、嘔吐的發(fā)生,并易誘發(fā)低血壓。
[Abstract]:Objective: to systematically evaluate the efficacy and safety of amifostine in the prevention of peripheral neurotoxicity (CIPN) induced by chemotherapy, and to provide evidence-based reference for clinical practice. Methods: the PubMed,EMBase,Cochrane Library, Chinese Journal full-text Database, Wanfang Database and Chinese Sci-tech Journal Database were searched by computer. The (RCT), data of patients with tumor were collected and compared with chemotherapy alone (control group). The quality of (RCT), was evaluated by improved Jadad scale. Meta analysis was carried out by RevMan 5.3 statistical software. Results: a total of 1552 patients with 20 items of RCT, were included. Meta-analysis showed that the total incidence of CIPN [RR=0.57,95%CI (0.45,0.72), P0.001], the incidence of severe CIPN [RR=0.47,95%CI (0.32, 0.69), P0.001] were significantly lower than those in the control group, the incidence of nausea [RR=1.31,95%CI (1.03, 1.67), P 鈮，

本文編號：2517367